Pfizer Net Acquisitions/Divestitures 2010-2024 | PFE
Pfizer annual/quarterly net acquisitions/divestitures history and growth rate from 2010 to 2024. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- Pfizer net acquisitions/divestitures for the quarter ending December 31, 2024 were $0M, a 100% decline year-over-year.
- Pfizer net acquisitions/divestitures for the twelve months ending December 31, 2024 were $0M, a 100% decline year-over-year.
- Pfizer annual net acquisitions/divestitures for 2024 were $0B, a 100% decline from 2023.
- Pfizer annual net acquisitions/divestitures for 2023 were $-43.43B, a 88.85% increase from 2022.
- Pfizer annual net acquisitions/divestitures for 2022 were $-22.997B, a 0% decline from 2021.
Pfizer Annual Net Acquisitions/Divestitures
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$-43,430 |
| 2022 |
$-22,997 |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$-10,861 |
| 2018 |
$N/A |
| 2017 |
$-1,000 |
| 2016 |
$-18,368 |
| 2015 |
$-16,466 |
| 2014 |
$-195 |
| 2013 |
$-15 |
| 2012 |
$10,800 |
| 2011 |
$-906 |
| 2010 |
$-273 |
| 2009 |
$-43,123 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$125.566B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
